| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/09/2001 | US6172058 Nervous system disorders; psychological disorders |
| 01/09/2001 | US6172055 Therapy, prevention a neurodegenerative diseases |
| 01/09/2001 | US6172047 Therapy for nervous system tumors |
| 01/09/2001 | US6172041 Nervous system disorders |
| 01/09/2001 | US6171835 ribH |
| 01/09/2001 | US6171598 GTP cyclohydrolase II (RIBA) |
| 01/09/2001 | US6171590 Treatment and prevention of inflammatory responses. |
| 01/09/2001 | US6171294 Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 01/09/2001 | CA2117483C [(benzodioxan, benzofuran or benzopyran)-alkylamino] alkyl substituted guanidines as selective vascoconstrictors |
| 01/05/2001 | CA2314536A1 Stable microemulsions for the administration of fatty acids to humans or animals, and use of these microemulsions |
| 01/04/2001 | WO2001000830A1 Sgip peptides |
| 01/04/2001 | WO2001000824A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 01/04/2001 | WO2001000812A2 22012, a novel human carboxypeptidase |
| 01/04/2001 | WO2001000676A1 Somatostatin agonists |
| 01/04/2001 | WO2001000665A2 Inhibitors of memapsin 2 and use thereof |
| 01/04/2001 | WO2001000663A2 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | WO2001000658A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/04/2001 | WO2001000655A2 Therapeutic peptides derived from subsequences of bpi |
| 01/04/2001 | WO2001000622A1 Prodrugs of carbamate inhibitors of impdh |
| 01/04/2001 | WO2001000619A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | WO2001000617A2 Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same |
| 01/04/2001 | WO2001000610A1 Substituted benzimidazole |
| 01/04/2001 | WO2001000603A1 Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/04/2001 | WO2001000587A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 01/04/2001 | WO2001000585A1 Pyrazolidinol compounds |
| 01/04/2001 | WO2001000566A2 Substituted phenoxyacetic acids |
| 01/04/2001 | WO2001000243A1 Pharmaceutical complex |
| 01/04/2001 | WO2001000235A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | WO2001000230A1 Drug composition containing lecithin-modified superoxide dismutase |
| 01/04/2001 | WO2001000229A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | WO2001000221A2 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | WO2001000210A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | WO2001000206A1 Vla-4 inhibitor compounds |
| 01/04/2001 | WO2001000205A1 Pharmaceutical composition containing sibutramine and orlistat |
| 01/04/2001 | WO2001000202A1 Use of fluoxetine, paroxetine and other srsi as medicaments for increasing the capacity to refrain from consuming substances or having activities which create dependence |
| 01/04/2001 | WO2001000193A2 Zinc ionophores as anti-apoptotic agents |
| 01/04/2001 | WO2001000186A2 New use of 1,2,4-triazolo'1,5-a! pyrimidines |
| 01/04/2001 | WO2001000185A2 1,4-denzothiazepines to treat obesity related disorders |
| 01/04/2001 | WO2001000181A2 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/04/2001 | WO2001000145A1 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 01/04/2001 | WO2001000082A1 Imaging the dopamine transporter to determine ad-hd |
| 01/04/2001 | WO2001000047A1 Prophylactic dietary supplement based on milk |
| 01/04/2001 | WO2000062798A3 Angiogenic growth factors for treatment of peripheral neuropathy |
| 01/04/2001 | WO2000060082A3 Vesicle associated proteins |
| 01/04/2001 | WO2000059907A3 Pyrazolotriazines as crf antagonists |
| 01/04/2001 | WO2000059449A3 Purine derivatives having phosphodiesterase iv inhibition activity |
| 01/04/2001 | WO2000052145A3 Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| 01/04/2001 | WO2000051684A3 Regulators of coenzyme-a-independent transacylase as psychotropic drugs |
| 01/04/2001 | WO2000029438A9 Egf-like nucleic acids and polypeptides and uses thereof |
| 01/04/2001 | WO2000026251A9 A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX |
| 01/04/2001 | DE19930454A1 Feste Paroxetin enthaltende Zubereitungen Solid preparations containing paroxetine |
| 01/04/2001 | CA2385798A1 Substituted phenoxyacetic acids |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377265A1 Somatostatin agonists |
| 01/04/2001 | CA2377200A1 Pyrazolidinol compounds |
| 01/04/2001 | CA2377186A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | CA2376935A1 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | CA2376914A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | CA2376886A1 Therapeutic agents |
| 01/04/2001 | CA2376307A1 Novel piperazinylalkylthiopyrimidine derivatives,pharmaceutical composi tions containing the same,and a process for the preparation of the active substance |
| 01/04/2001 | CA2376023A1 Therapeutic agents |
| 01/04/2001 | CA2375972A1 Pharmaceutical composition containing sibutramine and orlistat |
| 01/04/2001 | CA2375952A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | CA2375852A1 Zinc ionophores as anti-apoptotic agents |
| 01/04/2001 | CA2374610A1 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | CA2369308A1 Vla-4 inhibitor compounds |
| 01/04/2001 | CA2369145A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | CA2365341A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/03/2001 | EP1065215A1 Homomeric and heteromeric AMPA receptors |
| 01/03/2001 | EP1065205A1 Heteroaromatic derivatives |
| 01/03/2001 | EP1064967A2 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine |
| 01/03/2001 | EP1064966A2 Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine |
| 01/03/2001 | EP1064965A2 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 01/03/2001 | EP1064949A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064948A2 Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine |
| 01/03/2001 | EP1064937A1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/03/2001 | EP1064936A1 Novel composition of paroxetine methanesulfonate |
| 01/03/2001 | EP1064376A2 GFR$g(a)3 AND ITS USES |
| 01/03/2001 | EP1064375A2 Human calcium-binding proteins |
| 01/03/2001 | EP1064298A2 Inhibitors of caspases |
| 01/03/2001 | EP1064295A1 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS |
| 01/03/2001 | EP1064284A1 Hypnotic beta-carboline derivatives, process for their preparation and their use as medicinal products |
| 01/03/2001 | EP1064283A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors |
| 01/03/2001 | EP1064282A1 Crystalline form of paroxetine |
| 01/03/2001 | EP1064274A1 Benzenesulfonamide derivatives and their use as medicaments |
| 01/03/2001 | EP1064262A1 Substituted isoindolones and their use as cyclic gmp modulators in medicaments |
| 01/03/2001 | EP1064256A1 Bicyclo [2.2.1] heptanes and related compounds |
| 01/03/2001 | EP1064254A2 Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents |
| 01/03/2001 | EP1064021A1 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 01/03/2001 | EP1064013A1 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES |
| 01/03/2001 | EP1064003A1 Neurotrophic properties of ipgs and ipg analogues |
| 01/03/2001 | EP1063999A1 Epiallopregnanolone in the treatment of cns disorders |
| 01/03/2001 | EP1063996A1 Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v 1a? and v 2? receptors |
| 01/03/2001 | EP1063995A1 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator |
| 01/03/2001 | EP1063993A1 Paroxetine compositions |
| 01/03/2001 | EP1063984A1 Inflammatory cell inhibitors |
| 01/03/2001 | EP1063982A2 Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
| 01/03/2001 | EP1063980A2 Methods for decreasing beta amyloid protein production |
| 01/03/2001 | EP1063978A1 Method of treating neuroma pain |
| 01/03/2001 | EP0815126B1 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition |